Results 1 to 10 of about 12,502 (244)

Does Levosimendan hasten veno-arterial ECMO weaning? A propensity score matching analysis [PDF]

Annals of Intensive Care
Background Preliminary evidence from small, single-center studies suggests levosimendan may improve the likelihood of successful venoarterial extracorporeal membrane oxygenation (VA-ECMO) weaning in patients with cardiogenic shock.
Nicolas Paulo, Antoine Kimmoun, David Hajage, Pierre Hubert, David Levy, Marc Pineton de Chambrun, Juliette Chommeloux, Ouriel Saura, Grégoire Del Marmol, Quentin Moyon, Guillaume Hékimian, Melchior Gautier, Charles Edouard Luyt, Guillaume Lebreton, Bruno Levy, Alain Combes, Matthieu Schmidt   +16 more
doaj   +3 more sources

The Effects of the Levosimendan Metabolites OR-1855 and OR-1896 on Endothelial Pro-Inflammatory Responses

Biomedicines, 2023
The calcium sensitizer levosimendan is used for the treatment of acute decompensated heart failure. A small portion (4–7%) of levosimendan is metabolized to the pharmacologically active metabolite OR-1896 via the inactive intermediate OR-1855.
Hannah Kipka, Rebecca Schaflinger, Roland Tomasi, Kristin Pogoda, Hanna Mannell   +4 more
doaj   +2 more sources

Use of levosimendan combined with Shenfu injection to treat acute heart failure patients with hypotension: a prospective randomized controlled single-blind study

BMC Cardiovascular Disorders, 2022
Background Levosimendan can improve clinical symptoms and the cardiorenal rescue success rate, and stabilize hemodynamic parameters in individuals suffering from acute decompensated heart failure.
Miaomiao Li, Yue Zhang, Qianli Wan, Yiou Li, Tianzhen Qu, Fang Yuan   +5 more
doaj   +2 more sources

Effect of levosimendan treatment in cardiac surgery: a network meta-analysis of randomized controlled trials [PDF]

Frontiers in Cardiovascular Medicine
BackgroundThe prophylactic administration of levosimendan in patients undergoing cardiac surgery remains clinically contentious, particularly regarding its efficacy and safety in improving key postoperative outcomes, such as cardiac function, renal ...
Binlu Zhu, Wanling Zhao, Yifei Li
doaj   +2 more sources

The Effects of Levosimendan on Microcirculation and Peripheral Perfusion in Septic Shock: A Pilot Study [PDF]

Life
Septic patients can show multiorgan failure even after an apparent recovery of hemodynamic stability. The underlying mechanism is unclear, but the main pathological element is microcirculation impairment, leading to insufficient oxygen delivery.
Veronica Gagliardi, Francesco Ceccherelli, Antonello Lovato, Giuseppe Gagliardi   +3 more
doaj   +2 more sources

The Coadministration of Levosimendan and Exenatide Offers a Significant Cardioprotective Effect to Isolated Rat Hearts against Ischemia/Reperfusion Injury

Journal of Cardiovascular Development and Disease, 2022
(1) Background: The present study aims to investigate the effect of administration of Levosimendan and Exenatide in various concentrations, as well as of the coadministration of those agents in an ischemia–reperfusion injury isolated heart model.
Vasileios Leivaditis, Efstratios Koletsis, Nikolaos Tsopanoglou, Nikolaos Charokopos, Cristian D’Alessandro, Konstantinos Grapatsas, Efstratios Apostolakis, Effrosyni Choleva, Maria Plota, Andreas Emmanuil, Manfred Dahm, Dimitrios Dougenis   +11 more
doaj   +1 more source

Clinical outcomes of levosimendan versus dobutamine in patients with acute decompensated heart failure with reduced ejection fraction and impaired renal function

Indian Heart Journal, 2021
To assess the clinical outcomes of levosimendan and dobutamine in patients with acute decompensated heart failure with reduced ejection fraction and impaired renal function in Indian scenario.
Basil John, Pharm D, Mariya Babu, Pharm D, Sandramol shaji, Pharm D, Suja Abraham, Jabir Abdullakutty   +4 more
doaj   +1 more source

Does the cardiovascular drug levosimendan prevent iodinated contrast medium nephrotoxicity with glycerol aggravation in rats?

European Radiology Experimental, 2021
Background We investigated whether levosimendan prevents contrast medium nephrotoxicity with glycerol aggravation in rats. Methods Forty-eight Wistar albino rats were assigned to eight groups (n = 6 × 8).
Irmak Durur-Subasi, Duygu Kose, Muhammed Yayla, Busra Sirin, Adem Karaman, Ilknur Calik, Fatih Alper   +6 more
doaj   +1 more source

Influence of timing of Levosimendan administration on outcomes in cardiac surgery

Frontiers in Cardiovascular Medicine, 2023
PurposeThough a subgroup analysis has shown improved survival for patients suffering severely reduced ventricular function undergoing coronary artery bypass grafting, RCTs were not able to demonstrate overall beneficial effects of perioperative ...
Fridtjof Schiefenhövel, Fridtjof Schiefenhövel, Fridtjof Schiefenhövel, Christian Berger, Liubov Penkova, Herko Grubitzsch, Bernhard Haller, Alexander Meyer, Alexander Meyer, Matthias Heringlake, Michael Sander, Joachim M. Erb, Felix Balzer, Sascha Treskatsch   +13 more
doaj   +1 more source

Preconditioning with levosimendan reduces postoperative low cardiac output in moderate-severe systolic dysfunction patients who will undergo elective coronary artery bypass graft surgery: a cost-effective strategy

Journal of Cardiothoracic Surgery, 2020
Background Patients with moderate-severe systolic dysfunction undergoing coronary artery bypass graft have a higher incidence of postoperative low cardiac output. Preconditioning with levosimendan may be a useful strategy to prevent this complication. In
Juan José Jiménez-Rivera, Andrea Álvarez-Castillo, Jorge Ferrer-Rodríguez, José Luis Iribarren-Sarrías, Martín Jesús García-González, Pablo Jorge-Pérez, Juan Lacalzada-Almeida, Rosalía Pérez-Hernández, Javier Montoto-López, Rafael Martínez-Sanz   +9 more
doaj   +1 more source